New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
10:51 EDTFDO, COV, IGT, BIIB, SHPG, TIBX, NVDA, CZR, OREX, ESIOptions with increasing implied volatility
Options with increasing implied volatility: ESI OREX CZR NVDA TIBX SHPG BIIB IGT COV FDO
News For ESI;OREX;CZR;NVDA;TIBX;SHPG;BIIB;IGT;COV;FDO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 22, 2015
15:09 EDTCZRBankruptcy judge rules Caesar's must face suits, Bloomberg reports
Subscribe for More Information
14:56 EDTCZRJudge won't halt creditor lawsuits against Caesar's parent, WSJ reports
Subscribe for More Information
14:51 EDTCZRCaesar's halted for circuit breaker after falling to $6.31
Subscribe for More Information
14:01 EDTCZRCaesar's July weekly 7 straddle priced for 33% movement into court ruling
Subscribe for More Information
14:01 EDTCZRCaesar's July weekly volatility spikes to 490 into court ruling
Subscribe for More Information
12:04 EDTCZRCaesar's volatility spikes into court ruling
Subscribe for More Information
10:59 EDTBIIBBiogen drops after reporting data on Alzheimer's drug
The shares of Biogen (BIIB) are falling after the company released data on its Alzheimer's treatment candidate, aducanumab. Peer Eli Lilly (LLY) also reported data this morning on its own experimental Alzheimer's drug, solanezumab. BIOGEN: Biogen's data "does not inspire confidence," Piper analyst Joshua Schimmer wrote in a note to investors today. The 6 mg dose of the drug performed similarly to the 1mg dose, and was barely better than the placebo, the analyst stated. The cognitive and functional performance of the patients who took the 6 mg dose did not improve by a statistically significant amount, while the results of patients taking the other doses were "noisy,"Schimmer stated. Additionally, indications of excess fluid in the brain was observed in a significant number of patients, representing an additional problem for the treatment, the analyst believes. The data "is far from inspiring confidence" and makes the outlook for aducanumab "more speculative than ever," Schimmer contended. LILLY: Also this morning, Eli Lilly presented results from a pre-specified secondary analysis of several Phase 3 studies at the Alzheimer's Association International Conference. According to the company, the results suggest the treatment effect of solanezumab was preserved within a pre-specified amount in patients with mild Alzheimer's disease who received solanezumab earlier in the disease compared to patients who began treatment at a later point. Treatment differences in cognition and function between early-start and delayed-start groups at the end of the placebo-controlled period were preserved at the primary time point of 108 weeks within a pre-defined margin. Treatment differences in cognition and function between early-start and delayed-start groups at the end of the placebo-controlled period were also preserved at an additional time point of 132 weeks within a pre-defined margin.The differences at 108 weeks and at at 132 weeks remained statistically significant, the company said. PRICE ACTION: In morning trading, Biogen fell 3% to $397.43 while Eli Lilly shares rose 0.6% to $86.11.
10:01 EDTBIIBOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:28 EDTBIIBBiogen downgraded to Neutral at Piper Jaffray after Alzheimer's data
Subscribe for More Information
09:22 EDTBIIBBiogen downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
09:07 EDTBIIBOn The Fly: Pre-market Movers
Subscribe for More Information
07:19 EDTBIIBBiogen drops 4.8% to $390 after reporting Alzheimer's drug data
06:50 EDTBIIBBiogen's Alzheimer's candidate shows reduction of clinical decline
Subscribe for More Information
July 21, 2015
16:28 EDTCZROn The Fly: Top stock stories for Tuesday
Subscribe for More Information
12:21 EDTCZROn The Fly: Top stock stories at midday
Subscribe for More Information
06:24 EDTBIIBPiper expects 'stronger, bolder' move from Biogen
Subscribe for More Information
06:12 EDTBIIBBiogen implied volatility of 50 at upper end of index
05:07 EDTCZRCaesar's, CEOC, reach agreement with group of second lien noteholders
Subscribe for More Information
July 20, 2015
07:32 EDTBIIBAlzheimer's Association to hold a conference
Subscribe for More Information
July 17, 2015
08:07 EDTIGTInternational Game signs five-year extension agreement with Maryland Lottery
International Game has entered into a five-year extension agreement with the Maryland Lottery and Gaming Control Commission to continue providing the Company's INTELLIGEN central monitoring and control system for the existing video lottery terminal program at the state's five licensed VLT venues: Hollywood Casino Perryville, The Casino at Ocean Downs, Maryland Live! Casino, Rocky Gap Resort and Casino, and Horseshoe Casino Baltimore. Additionally under the extension agreement, the Company will provide technology and services to connect the VLTs at the state's sixth licensed VLT venue, MGM National Harbor, which is expected to open in the third or fourth quarter of 2016, to INTELLIGEN.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use